Evan David Seigerman Analyst PerformanceBioPharma Analyst at BMO Capital MarketsEvan David Seigerman is a stock analyst at BMO Capital Markets, covering 8 publicly traded companies across a range of sectors. Over the past year, Evan David Seigerman has issued 10 stock ratings, including buy, hold, and sell recommendations. While full access to Evan David Seigerman's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan David Seigerman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Ratings, Coverage, and Performance StatisticsAnalyst RatingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings10 Last 0 YearsBuy Recommendations80.00% 8 Buy RatingsCompanies Covered8 Unique Companies Ratings Distribution10RatingsDistribution of strong buy, buy, hold, and sell ratings by Evan David Seigerman.RatingPercentageCount Strong Buy0.0%0 ratings Buy80.0%8 ratings Hold10.0%1 ratings Sell10.0%1 ratingsOut of 10 total stock ratings issued by Evan David Seigerman at BMO Capital Markets, the majority (80.0%) have been Buy recommendations, followed by 10.0% Hold and 10.0% Sell.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ75.0% of companies on NASDAQ6 companiesNYSE25.0% of companies on NYSE2 companiesEvan David Seigerman, an analyst at BMO Capital Markets, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical8 companies100.0%Evan David Seigerman of BMO Capital Markets specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies75.0%LARGE CAP PHARMA2 companies25.0% About Evan David SeigermanEvan is a Managing Director and Senior Research Analyst at BMO Capital Markets covering Biotechnology (Large and SMid Cap) and US Major Pharmaceuticals. His responsibilities also include leading the therapeutics research effort at BMO, shaping strategy and growing impact of the broader franchise. Prior to joining BMO, Evan was a senior research analyst at Credit Suisse, also covering Biotechnology. He started his Wall Street Career at Deutsche Bank and later was on the #2 Institutional Investor ranked Biopharma team at Barclays. Before equity research, Evan was a strategy consultant for Major Pharma and Biotechnology clients. Recently, Evan was named a Rising Star of Equity Research by Business Insider and is consistently recognized by investors as a leading voice in the biotechnology space. He has been featured in countless media outlets, including CNBC, PBS News Hour, BNN Canada, The Wall Street Journal, Barron’s, The Economist, Kiplinger’s Personal Finance, The New York Times, and industry trade publications. Evan holds a BBA in Finance and Accounting and BA in Spanish, both from the University of Michigan. Evan David Seigerman's Ratings History at BMO Capital Markets Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsREPLReplimune Group7/23/2025Downgrade$2.81$2.00Underperform$0.0000.00% ROINGNENeurogene6/12/2025Reiterated Rating$21.56$26.00Outperform$0.0000.00% ROIREGNRegeneron Pharmaceuticals6/2/2025Lower Price Target$489.01$600.00Outperform$0.0000.00% ROIMRUSMerus5/23/2025Set Price Target$54.31$110.00Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals5/19/2025Boost Price Target$21.94$28.00Outperform$0.0000.00% ROIARVNArvinas5/5/2025Lower Price Target$7.72$10.00Outperform$0.0000.00% ROIREGNRegeneron Pharmaceuticals4/30/2025Lower Price Target$581.07$800.00Outperform$0.0000.00% ROINVONovo Nordisk A/S4/17/2025Reiterated Rating$62.88$64.00Market Perform$0.0000.00% ROIABBVAbbVie2/3/2025Boost Price Target$183.90$215.00Outperform$0.0000.00% ROIREPLReplimune Group1/22/2025Boost Price Target$13.20$27.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.